We highly recommend enabling Javascript while using the BlackBoxRX site.


Lactic Acidosis; Severe Hepatomegaly with Steatosis and Post Treatment Exacerbation of Hepatitis B

  • Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate, a component of ATRIPLA, in combination with other antiretrovirals.
  • ATRIPLA is not approved for the treatment of chronic hepatitis B virus (HBV) infection and the safety and efficacy of ATRIPLA have not been established in patients coinfected with HBV and HIV-1. Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued EMTRIVA or VIREAD, which are components of ATRIPLA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue ATRIPLA. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
  • ATRIPLA is contraindicated to be coadministered with voriconazole or elbasvir/grazoprevir.

Patient Counseling Information


Package Inserts


Updated August 2018